William S. Dalton, PhD, MD

Where You Are:
William S. Dalton, PhD, MD

Senior Member

"Dr. Dalton's research examines the influence of the tumor microenvironment on tumor cell survival and progression."

Office  (888) 663-3488

Education And Training
  • Fellow, University of Arizona, 1985 - Oncology
  • Fellow, University of Arizona, 1985 - Clinical Pharmacology
  • Resident, University of Arizona, 1983 - Medicine
  • Intern, Indiana University, 1981 - Medicine
  • MD, Indiana University, 1980
  • PhD, Indiana University, 1976 - Toxicology/Medical Life Sciences
  • BA, University of New Mexico, 1971 - Chemistry/Philosophy


Dr. Dalton and his colleagues have found that elements of the bone marrow microenvironment, including extracellular matrices and normal stromal elements, protect hematologic malignant cells from drug-induced cell death. They proposed that environmentally mediated drug resistance (EMDR) protects tumor cells from stress and cell death by two mechanisms: 1) a paracrine mechanism due to soluble cytokine factors produced as a result of the tumor cell:environment interaction; and 2) a physical contact mechanism they have termed 'cell adhesion'mediated drug resistance" (CAM-DR). Their initial studies comparing genotypic and phenotypic profiles of drug resistance indicate that EMDR is less complex than acquired drug resistance. Focusing on EMDR may ultimately prevent the emergence of acquired drug resistance and enhance drug therapy for hematologic malignancies.

Dr. Dalton and his colleagues have examined the signal transduction pathways associated with tumor cells and the microenvironment with the idea that a thorough understanding of these pathways will lead to new therapeutic targets. They reported that adhesion to fibronectin of myeloma cell lines causes a reversible G1 arrest, which correlated with increased levels of p27kip1. Myeloma is characterized as a slow-growing malignancy, and the bone marrow microenvironment may participate in regulating the growth of the disease. They also showed that adhesion-mediated increases in p27kip1 levels contribute to the CAM-DR phenotype, as reducing p27kip1 levels with antisense techniques partially reversed the phenotype.

Similarly, Dr. Dalton and his colleagues, in collaboration with Dr. Gabrilovich of the Immunology Program, investigated the role of Notch family proteins in hematologic tumor cell line growth and response to chemotherapeutic drugs. Interaction with bone marrow stroma activated Notch signaling in tumor cells. However, activation of only Notch-1, but not Notch-2, resulted in protection of tumor cells from melphalan- and mitoxantrone-induced apoptosis. This protection was associated with up-regulation of p21WAF/Cip and inhibition of cell growth. Overexpression of Notch-1 in Notch-1'negative U266 myeloma cells up-regulated p21 and resulted in protection from drug-induced apoptosis. This was the first report demonstrating that Notch-1 signaling may be a primary mechanism mediating the bone marrow stromal influence on hematologic malignant cell growth and survival.

  • Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Brit J Cancer. 2014 Nov;111(10):1932-1944. Pubmedid: 25290091.
  • Coppola D, Balducci L, Chen DT, Loboda A, Nebozhyn M, Staller A, Fulp WJ, Dalton W, Yeatman T, Brem S. Senescence-associated-gene signature identifies genes linked to age, prognosis, and progression of human gliomas. J Geriatr Oncol. 2014 Sep. Pubmedid: 25220188.
  • Shaikh AR, Butte AJ, Schully SD, Dalton WS, Khoury MJ, Hesse BW. Collaborative biomedicine in the age of big data: the case of cancer. J Med Internet Res. 2014 Apr;16(4):e101. Pubmedid: 24711045.
  • Abernethy A, Abrahams E, Barker A, Buetow K, Burkholder R, Dalton WS, Foti M, Frueh F, Gaynor RB, Kean M, Khan Z, Lessor T, Lichtenfeld JL, Mendelsohn J, Van't Veer L. Turning the tide against cancer through sustained medical innovation: the pathway to progress. Clin Cancer Res. 2014 Mar;20(5):1081-1086. Pubmedid: 24523437.
  • Baz RC, Shain KH, Hussein MA, Lee JH, Sullivan DM, Finleyoliver E, Nardelli LA, Nodzon LA, Zhao X, Ochoa-Bayona JL, Nishihori T, Dalton WS, Alsina M. Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma. Am J Hematol. 2014 Jan;89(1):62-67. Pubmedid: 24030918.
  • Zhao X, Lwin T, Zhang X, Huang A, Wang J, Marquez VE, Chen-Kiang S, Dalton WS, Sotomayor E, Tao J. Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity. Leukemia. 2013 Dec;27(12):2341-2350. Pubmedid: 23538750. Pmcid: PMC4015113.
  • Lwin T, Zhao X, Cheng F, Zhang X, Huang A, Shah B, Zhang Y, Moscinski LC, Choi YS, Kozikowski AP, Bradner JE, Dalton WS, Sotomayor E, Tao J. A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas. J Clin Invest. 2013 Nov;123(11):4612-4626. Pubmedid: 24216476. Pmcid: PMC3809771.
  • Baz R, Miladinovic B, Patel A, Ho VQ, Shain KH, Alsina M, Nishihori T, Ochoa-Bayona JL, Sullivan DM, Dalton WS, Djulbegovic B. Sequence of novel agents in multiple myeloma: an instrumental variable analysis. Leuk Res. 2013 Sep;37(9):1077-1082. Pubmedid: 23809054.
  • Boucher K, Parquet N, Widen R, Shain K, Baz R, Alsina M, Koomen J, Anasetti C, Dalton W, Perez LE. Stemness of B-cell progenitors in multiple myeloma bone marrow. Clin Cancer Res. 2012 Nov;18(22):6155-6168. Pubmedid: 22988056. Pmcid: PMC3500436.
  • Cantley LC, Dalton WS, DuBois RN, Finn OJ, Futreal PA, Golub TR, Hait WN, Lozano G, Maris JM, Nelson WG, Sawyers CL, Schreiber SL, Spitz MR, Steeg PS. AACR Cancer Progress Report 2012. Clin Cancer Res. 2012 Nov;18(21 Suppl):S1-100. Pubmedid: 22977188.
  • Lichter DI, Danaee H, Pickard MD, Tayber O, Sintchak M, Shi H, Richardson PG, Cavenagh J, Bladé J, Façon T, Niesvizky R, Alsina M, Dalton W, Sonneveld P, Lonial S, van de Velde H, Ricci D, Esseltine DL, Trepicchio WL, Mulligan G, Anderson KC. Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood. 2012 Nov;120(23):4513-4516. Pubmedid: 23018640. Pmcid: PMC3757460.
  • Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R, Zhang Y, Chan JC, Fu K, Marquez VE, Chen-Kiang S, Moscinski LC, Seto E, Dalton WS, Wright KL, Sotomayor E, Bhalla K, Tao J. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer Cell. 2012 Oct;22(4):506-523. Pubmedid: 23079660. Pmcid: PMC3973134.
  • Wilson DS, Fang B, Dalton WS, Meade CD, Koomen JM. An ET-CURE pilot project supporting undergraduate training in cancer research, emerging technology, and health disparities. J Cancer Educ. 2012 Jun;27(3):418-427. Pubmedid: 22528637. Pmcid: PMC3439555.
  • Zhang X, Chen X, Lin J, Lwin T, Wright G, Moscinski LC, Dalton WS, Seto E, Wright K, Sotomayor E, Tao J. Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene. 2012 Jun;31(24):3002-3008. Pubmedid: 22002311. Pmcid: PMC3982396.
  • Nishihori T, Alekshun TJ, Shain K, Sullivan DM, Baz R, Perez L, Pidala J, Kharfan-Dabaja MA, Ochoa-Bayona JL, Fernandez HF, Yarde DN, Oliveira V, Fulp W, Han G, Kim J, Chen DT, Raychaudhuri J, Dalton W, Anasetti C, Alsina M. Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. Brit J Haematol. 2012 Jun;157(5):553-563. Pubmedid: 22449149. Pmcid: PMC4030553.
  • Xiang Y, Remily-Wood ER, Oliveira V, Yarde D, He L, Cheng JQ, Mathews L, Boucher K, Cubitt C, Perez L, Gauthier TJ, Eschrich SA, Shain KH, Dalton WS, Hazlehurst L, Koomen JM. Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma. Mol Cell Proteomics. 2011 Nov;10(11):M110.005520. Pubmedid: 21846842. Pmcid: PMC3226396.
  • Remily-Wood ER, Liu RZ, Xiang Y, Chen Y, Thomas CE, Rajyaguru N, Kaufman LM, Ochoa JE, Hazlehurst L, Pinilla-Ibarz J, Lancet J, Zhang G, Haura E, Shibata D, Yeatman T, Smalley KS, Dalton WS, Huang E, Scott E, Bloom GC, Eschrich SA, Koomen JM. A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. Proteomics Clin Appl. 2011 Aug;5(7-8):383-396. Pubmedid: 21656910. Pmcid: PMC3530891.
  • Lin J, Lwin T, Zhao JJ, Tam W, Choi YS, Moscinski LC, Dalton WS, Sotomayor EM, Wright KL, Tao J. Follicular dendritic cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas. Leukemia. 2011 Jan;25(1):145-152. Pubmedid: 20966935. Pmcid: PMC3083119.
  • Li M, Chen F, Clifton N, Sullivan DM, Dalton WS, Gabrilovich DI, Nefedova Y. Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect. Mol Cancer Ther. 2010 Dec;9(12):3200-3209. Pubmedid: 21159606. Pmcid: PMC3058809.
  • Dalton WS, Sullivan DM, Yeatman TJ, Fenstermacher DA. The 2010 Health Care Reform Act: a potential opportunity to advance cancer research by taking cancer personally. Clin Cancer Res. 2010 Dec;16(24):5987-5996. Pubmedid: 21169252.
  • Lwin T, Lin J, Choi YS, Zhang X, Moscinski LC, Wright KL, Sotomayor EM, Dalton WS, Tao J. Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a. Blood. 2010 Dec;116(24):5228-5236. Pubmedid: 20841506. Pmcid: PMC3012540.
  • Meads MB, Li ZW, Dalton WS. A novel TNF receptor-associated factor 6 binding domain mediates NF-kappa B signaling by the common cytokine receptor beta subunit. J Immunol. 2010 Aug;185(3):1606-1615. Pubmedid: 20622119. Pmcid: PMC3050047.
  • Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W, Dessureault S, Moscinski LC, Rezania D, Dalton WS, Sotomayor E, Tao J, Cheng JQ. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood. 2010 Apr;115(13):2630-2639. Pubmedid: 20086245. Pmcid: PMC2852365.
  • Perez LE, Parquet N, Meads M, Anasetti C, Dalton W. Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma. Eur J Haematol. 2010 Mar;84(3):212-222. Pubmedid: 19922463.
  • Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA. Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb;85(2):197-199. Pubmedid: 20118399. Pmcid: PMC2813833.
  • Yarde DN, Oliveira V, Mathews L, Wang X, Villagra A, Boulware D, Shain KH, Hazlehurst LA, Alsina M, Chen DT, Beg AA, Dalton WS. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res. 2009 Dec;69(24):9367-9375. Pubmedid: 19934314.
  • Richardson PG, Weller E, Jagannath S, Avigan DE, Alsina M, Schlossman RL, Mazumder A, Munshi NC, Ghobrial IM, Doss D, Warren DL, Lunde LE, McKenney M, Delaney C, Mitsiades CS, Hideshima T, Dalton W, Knight R, Esseltine DL, Anderson KC. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol. 2009 Dec;27(34):5713-5719. Pubmedid: 19786667. Pmcid: PMC2799050.
  • Shain KH, Dalton WS. Environmental-mediated drug resistance: a target for multiple myeloma therapy. Expert Rev Hematol. 2009 Dec;2(6):649-662. Pubmedid: 21082957.
  • Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009 Sep;9(9):665-674. Pubmedid: 19693095.
  • Nair RR, Emmons MF, Cress AE, Argilagos RF, Lam K, Kerr WT, Wang HG, Dalton WS, Hazlehurst LA. HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells. Mol Cancer Ther. 2009 Aug;8(8):2441-2451. Pubmedid: 19671765. Pmcid: PMC2761715.
  • Chen RQ, Yang QK, Chen YL, Oliveira VA, Dalton WS, Fearns C, Lee JD. Kinome siRNA screen identifies SMG-1 as a negative regulator of hypoxia-inducible factor-1alpha in hypoxia. J Biol Chem. 2009 Jun;284(25):16752-16758. Pubmedid: 19406746. Pmcid: PMC2719310.
  • Shain KH, Yarde DN, Meads MB, Huang M, Jove R, Hazlehurst LA, Dalton WS. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res. 2009 Feb;69(3):1009-1015. Pubmedid: 19155309. Pmcid: PMC2680075.
  • Lwin T, Crespo LA, Wu A, Dessureault S, Shu HB, Moscinski LC, Sotomayor E, Dalton WS, Tao J. Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin's B lymphoma cells from apoptosis. Leukemia. 2009 Jan;23(1):170-177. Pubmedid: 18843286.
  • Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS, Cheng JQ. MicroRNA-155 Is regulated by transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol. 2008 Nov;28(22):6773-6784. Pubmedid: 18794355.
  • Peramo A, Meads MB, Dalton WS, Matthews WG. Static adhesion of cancer cells to glass surfaces coated with glycosaminoglycans. Colloids Surf B Biointerfaces. 2008 Nov;67(1):140-144. Pubmedid: 18815015.
  • Koomen JM, Haura EB, Bepler G, Sutphen R, Remily-Wood ER, Benson K, Hussein M, Hazlehurst LA, Yeatman TJ, Hildreth LT, Sellers TA, Jacobsen PB, Fenstermacher DA, Dalton WS. Proteomic contributions to personalized cancer care. Mol Cell Proteomics. 2008 Oct;7(10):1780-1794. Pubmedid: 18664563. Pmcid: PMC2559938.
  • Yeatman TJ, Mule J, Dalton WS, Sullivan D. On the eve of personalized medicine in oncology. Cancer Res. 2008 Sep;68(18):7250-7252. Pubmedid: 18794109.
  • Nimmanapalli R, Gerbino E, Dalton W, Gandhi V, Alsina M. HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma. Brit J Haematol. 2008 Aug;142(4):551-561. Pubmedid: 18503584.
  • Meads M, Hazlehurst L, Dalton W. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res. 2008 May;14(9):2519-2526. Pubmedid: 18451212.
  • Oliveira V, Romanow WJ, Geisen C, Otterness DM, Mercurio F, Wang HG, Dalton WS, Abraham RT. A protective role for the human SMG-1 kinase against tumor necrosis factor-alpha-induced apoptosis. J Biol Chem. 2008 May;283(19):13174-13184. Pubmedid: 18326048. Pmcid: PMC2442360.
  • Perez L, Parquet N, Shain K, Nimmanapalli R, Alsina M, Anasetti C, Dalton W. Bone Marrow Stroma Confers Resistance to Apo2 Ligand/TRAIL in Multiple Myeloma inPart by Regulating c-FLIP. J Immunol. 2008 Feb;180(3):1545-1555. Pubmedid: 18209050.
  • Nefedova Y, Sullivan D, Bolick S, Dalton W, Gabrilovich D. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood. 2008 Feb;111(4):2220-2229. Pubmedid: 18039953.
  • Richardson P, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau J, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San Miguel J, Blade J, Boccadoro M, Cavenagh J, Alsina M, Rajkumar S, Lacy M, Jakubowiak A, Dalton W, Boral A, Esseltine D, Schenkein D, Anderson K. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007 Nov;110(10):3557-3560. Pubmedid: 17690257.
  • Lwin T, Hazlehurst LA, Dessureault S, Lai R, Bai W, Sotomayor E, Moscinski LC, Dalton WS, Tao J. Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. Blood. 2007 Sep;110(5):1631-1638. Pubmedid: 17502456. Pmcid: PMC1975846.
  • Lwin T, Hazlehurst LA, Li Z, Dessureault S, Sotomayor E, Moscinski LC, Dalton WS, Tao J. Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells. Leukemia. 2007 Jul;21(7):1521-1531. Pubmedid: 17476277.
  • Hazlehurst LA, Argilagos RF, Dalton WS. Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells. Brit J Haematol. 2007 Jan;136(2):269-275. Pubmedid: 17233818.
  • Turner JG, Gump JL, Zhang C, Cook JM, Marchion D, Hazlehurst L, Munster P, Schell MJ, Dalton WS, Sullivan DM. ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood. 2006 Dec;108(12):3881-3889. Pubmedid: 16917002. Pmcid: PMC1895461.
  • Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, Schlossman RL, Rajkumar SV, Desikan KR, Hideshima T, Munshi NC, Kelly-Colson K, Doss D, McKenney ML, Gorelik S, Warren D, Freeman A, Rich R, Wu A, Olesnyckyj M, Wride K, Dalton WS, Zeldis J, Knight R, Weller E, Anderson KC. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006 Nov;108(10):3458-3464. Pubmedid: 16840727. Pmcid: PMC1895441.
  • Li Z, Dalton W. Tumor microenvironment and drug resistance in hematologic malignancies. Blood Rev. 2006 Nov;20(6):333-42. Pubmedid: 16920238.
  • Dalton W, Anderson K. Synopsis of a roundtable on validating novel therapeutics for multiple myeloma. Clin Cancer Res. 2006 Nov;12(22):6603-6610. Pubmedid: 17121878.
  • Dalton W, Friend S. Cancer biomarkers--an invitation to the table. Science. 2006 May;312(5777):1165-1168. Pubmedid: 16728629.
  • Hazlehurst L, Argilagos R, Emmons M, Boulware D, Beam C, Sullivan D, Dalton W. Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells. Cancer Res. 2006 Feb;66(4):2338-2345. Pubmedid: 16489039.
  • Friedenberg W, Rue M, Blood E, Dalton W, Shustik C, Larson R, Sonneveld P, Greipp P. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer. 2006 Feb;106(4):830-838. Pubmedid: 16419071.
  • Yanamandra N, Colaco N, Parquet N, Buzzeo R, Boulware D, Wright G, Perez LE, Dalton W, Beaupre D. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res. 2006 Jan;12(2):591-599. Pubmedid: 16428505.
  • Buzzeo R, Enkemann S, Nimmanapalli R, Alsina M, Lichtenheld M, Dalton W, Beaupre D. Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341. Clin Cancer Res. 2005 Aug;11(16):6057-6064. Pubmedid: 16115951.
  • Chen Q, Van der Sluis P, Boulware D, Hazlehurst L, Dalton W. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood. 2005 Jul;106(2):698-705. Pubmedid: 15802532.
  • Richardson P, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau J, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel J, Blade J, Boccadoro M, Cavenagh J, Dalton W, Boral A, Esseltine D, Porter J, Schenkein D, Anderson K. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005 Jun;352(24):2487-2498. Pubmedid: 15958804.
  • Zhu K, Gerbino E, Beaupre DM, Mackley PA, Muro-Cacho C, Beam C, Hamilton AD, Lichtenheld MG, Kerr WG, Dalton W, Alsina M, Sebti SM. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood. 2005 Jun;105(12):4759-4766. Pubmedid: 15728126. Pmcid: PMC1895008.
  • Garrett CR, Fishman MN, Rago RR, Williams CC, Dellaportas AM, Mahany JJ, Lush RM, Dalton WS, Gollerkeri A, Cohen MB, Sullivan DM. Phase I study of a novel taxane BMS-188797 in adult patients with solid malignancies. Clin Cancer Res. 2005 May;11(9):3335-3341. Pubmedid: 15867232.
  • Dalton W. Drug resistance in hematologic malignancies. Clin Adv Hematol Oncol. 2005 Apr;3(4):267-268. Pubmedid: 16166998.
  • Dalton W. The "total cancer care" concept: linking technology and health care. Cancer Control. 2005 Apr;12(2):140-141. Pubmedid: 15855897.
  • Burdelya L, Kujawski M, Niu G, Zhong B, Wang T, Zhang S, Kortylewski M, Shain K, Kay H, Djeu J, Dalton W, Pardoll D, Wei S, Yu H. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol. 2005 Apr;174(7):3925-3931. Pubmedid: 15778348. Pmcid: PMC2632804.
  • Dalton WS. The proteasome. Semin Oncol. 2004 Dec;31(6 Suppl 16):3-9. Pubmedid: 15799238.
  • Dalton WS. Proteasome inhibition in hematologic malignancies: clinical update and practical applications. Oncology (Williston Park). 2004 Dec;18(14 Suppl 11):3. Pubmedid: 15688596.
  • Jung L, Holle L, Dalton WS. Discovery, Development, and clinical applications of bortezomib. Oncology (Williston Park). 2004 Dec;18(14 Suppl 11):4-13. Pubmedid: 15688597.
  • Richardson P, Schlossman R, Jagannath S, Alsina M, Desikan R, Blood E, Weller E, Mitsiades C, Hideshima T, Davies F, Doss D, Freeman A, Bosch J, PatinJ, Knight R, Zeldis J, Dalton W, Anderson K. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc. 2004 Jul;79(7):875-882. Pubmedid: 15244383.
  • Engel R, Valkov N, Gump J, Hazlehurst L, Dalton W, Sullivan D. The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells. Exp Cell Res. 2004 May;295(2):421-431. Pubmedid: 15093741.
  • Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T, Overton RM, Ahmann G, Bruzek LM, Adjei AA, Kaufmann SH, Wright JJ, Sullivan D, Djulbegovic B, Cantor AB, Greipp PR, Dalton WS, Sebti SM. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood. 2004 May;103(9):3271-3277. Pubmedid: 14726402.
  • Nefedova Y, Cheng P, Alsina M, Dalton W, Gabrilovich D. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood. 2004;103(9):3503-3510. Pubmedid: 14670925.
  • Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, Dalton W, Jove R, Pardoll D, Yu H. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004;10(1):48-54. Pubmedid: 14702634.
  • Dalton W, Hazlehurst L, Shain K, Landowski T, Alsina M. Targeting the bone marrow microenvironment in hematologic malignancies. Semin Hematol. 2004;41(2):1-5. Pubmedid: 15190509.
  • Hazlehurst L, Enkemann S, Beam C, Argilagos R, Painter J, Shain K, Saporta S, Boulware L, Moscinski L, Alsina M, Dalton W. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res. 2003 Nov;63(22):7900-7906. Pubmedid: 14633719.
  • Sabichi A, Modiano M, Lee J, Peng Y, Xu M, Villar H, Dalton W, Lippman S. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide. Clin Cancer Res. 2003 Jul;9(7):2400-2405. Pubmedid: 12855611.
  • Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia. 2003 Jun;17(6):1175-1182. Pubmedid: 12764386.
  • Rago RP, Einstein A, Lush R, Beer TM, Ko YJ, Henner WD, Bubley G, Merica EA, Garg V, Ette E, Harding MW, Dalton WS. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Cancer Chemother Pharmacol. 2003 Apr;51(4):297-305. Pubmedid: 12721757.
  • Bolick SC, Landowski TH, Boulware D, Oshiro MM, Ohkanda J, Hamilton AD, Sebti SM, Dalton WS. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. Leukemia. 2003 Feb;17(2):451-457. Pubmedid: 12592346.
  • Dalton W. The tumor microenvironment: focus on myeloma. Cancer Treat Rev. 2003;29:11-19. Pubmedid: 12738239.
  • Hazlehurst L, Landowski T, Dalton W. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene. 2003;22(47):7396-7402. Pubmedid: 14576847.
  • Landowski T, Olashaw N, Agrawal D, Dalton W. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells. Oncogene. 2003;22(16):2417-2421. Pubmedid: 12717418.
  • Anderson KC, Dalton WS. Synopsis of a research roundtable presented on cell signaling in myeloma: regulation of growth and apoptosis--opportunities for new drug discovery. Mol Cancer Ther. 2002 Dec;1(14):1361-1365. Pubmedid: 12516971.
  • Dalton W. Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of re. Clin Cancer Res. 2002 Dec;8(12):3643-3645. Pubmedid: 12473572.
  • Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene. 2002 Dec;21(57):8804-8816. Pubmedid: 12483533.
  • Dalton W. Drug resistance and drug development in multiple myeloma. Semin Oncol. 2002;29(6):21-25. Pubmedid: 12520481.
  • Shain K, Landowski T, Dalton W. Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J Immunol. 2002;168(5):2544-2553. Pubmedid: 11859150.
  • Burdelya L, Catlett-Falcone R, Levitzki A, Cheng F, Mora L, Sotomayor E, Coppola D, Sun J, Sebti S, Dalton W, Jove R, Yu H. Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone. Mol Cancer Ther. 2002;1(11):893-899. Pubmedid: 12481410.
  • Oshiro MM, Landowski TH, Catlett-Falcone R, Hazlehurst LA, Huang M, Jove R, Dalton WS. Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells. Clin Cancer Res. 2001 Dec;7(12):4262-4271. Pubmedid: 11751528.
  • Hazelhurst LA, Valkov N, Wisner L, Storey JA, Boulware D, Sullivan DM, Dalton WS. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood. 2001 Sep;98(6):1897-1903. Pubmedid: 11535527.
  • Grad J, Bahlis N, Reis I, Oshiro M, Dalton W, Boise L. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood. 2001 Aug;98(3):805-813. Pubmedid: 11468182.
  • Damiano JS, Hazlehurst LA, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia. 2001 Aug;15(8):1232-1239. Pubmedid: 11480565.
  • Dorr R, Karanes C, Spier C, Grogan T, Greer J, Moore J, Weinberger B, Schiller G, Pearce T, Litchman M, Dalton W, Roe D, List A. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. J Clin Oncol. 2001 Mar;19(6):1589-1599. Pubmedid: 11250987.
  • Niu G, Shain K, Huang M, Ravi R, Bedi A, Dalton W, Jove R, Yu H. Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res. 2001;61(8):3276-3280. Pubmedid: 11309279.
  • Landowski T, Moscinski L, Burke R, Buyuksal I, Painter J, Goldstein S, Dalton W. CD95 antigen mutations in hematopoietic malignancies. Leuk Lymphoma. 2001;42(5):835-846. Pubmedid: 11697638.
  • Shain K, Dalton W. Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. Mol Cancer Ther. 2001;1(1):69-78. Pubmedid: 12467240.
  • Dalton W, Bergsagel P, Kuehl W, Anderson K, Harousseau J. Multiple myeloma. Hematology (Am Soc Hematol Educ Program). 2001;157-177. Pubmedid: 11722983.
  • Hazlehurst L, Dalton W. Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev. 2001;20(1-2):43-50. Pubmedid: 11831646.
  • Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene. 2000 Sep;19(38):4319-4327. Pubmedid: 10980607.
  • Kudoh K, Ramanna M, Ravatn R, Elkahloun AG, Bittner ML, Meltzer PS, Trent JM, Dalton WS, Chin KV. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. 2000 Aug;60(15):4161-4166. Pubmedid: 10945624.
  • Scheffer G, Maliepaard M, Pijnenborg A, van Gastelen M, de Jong M, Schroeijers A, van der Kolk D, Allen J, Ross D, van der Valk P, Dalton W, Schellens J, Scheper R. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res. 2000 May;60(10):2589-2593. Pubmedid: 10825126.
  • Shain KH, Landowski TH, Buyuksal I, Cantor AB, Dalton WS. Clonal variability in CD95 expression is the major determinant in Fas-medicated, but not chemotherapy-medicated apoptosis in the RPMI 8226 multiple myeloma cell line. Leukemia. 2000 May;14(5):830-840. Pubmedid: 10803514.
  • Shain K, Landowski T, Dalton W. The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance. Curr Opin Oncol. 2000;12(6):557-563. Pubmedid: 11085455.
  • Damiano J, Dalton W. Integrin-mediated drug resistance in multiple myeloma. Leuk Lymphoma. 2000;38(1-2):71-81. Pubmedid: 10811449.
  • Fishman M, Dalton W. Considerations in the management of myeloma. Oncology (Huntingt). 2000;14:72-81. Pubmedid: 11195422.
  • Shtil A, Turner J, Dalton W, Yu H. Alternative pathways of cell death to circumvent pleiotropic resistance in myeloma cells: role of cytotoxic T-lymphocytes. Leuk Lymphoma. 2000;38(1-2):59-70. Pubmedid: 10811448.
  • Diaz J, Pow-Sang J, Mora L, Seigne J, Cantor A, Dalton W. Cytometric analysis of Fas and Bcl-2 expression in normal prostatic epithelium and prostate cancer. Urol Oncol. 2000;5(4):149-154. Pubmedid: 10869956.
  • Anderson K, Kyle R, Dalton W, Landowski T, Shain K, Jove R, Hazlehurst L, Berenson J. Multiple Myeloma: New Insights and Therapeutic Approaches. Hematology (Am Soc Hematol Educ Program). 2000;147-165. Pubmedid: 11701540.
  • Fishman M, Dalton W. Considerations in the management of myeloma. Oncology (Williston Park). 2000;14(11A):72-81. Pubmedid: 11195422.
  • Dalton W, Scheper R. Lung resistance-related protein: determining its role in multidrug resistance. J Natl Cancer Inst. 1999 Oct;91(19):1604-1605. Pubmedid: 10511581.
  • Landowski T, Shain K, Oshiro M, Buyuksal I, Painter J, Dalton W. Myeloma cells selected for resistance to CD95-mediated apoptosis are not cross-resistant to cytotoxic drugs: evidence for independent mechanisms of caspase activation. Blood. 1999 Jul;94(1):265-274. Pubmedid: 10381522.
  • Martinez R, Raghunand N, Lynch R, Bellamy W, Martinez G, Rojas B, Dalton W, Gillies R. pH and drug resistance. I. Functional expression of plasmalemmal V-type H+-ATPase in drug-resistant human breast carcinoma cell lines. Biochem Pharmacol. 1999 May;57(9):1037-1046. Pubmedid: 10796074.
  • Hazlehurst L, Foley N, Gleason-Guzman M, Hacker M, Cress A, Greenberger L, De Jong M, Dalton W. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res. 1999 Mar;59(5):1021-1028. Pubmedid: 10070958.
  • Damiano J, Cress A, Hazlehurst L, Shtil A, Dalton W. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999 Mar;93(5):1658-1667. Pubmedid: 10029595.
  • Bowman T, Yu H, Sebti S, Dalton W, Jove R. Signal transducers and activators of transcription: novel targets for anticancer therapeutics. Cancer Control. 1999;6(5):427-435. Pubmedid: 10758575.
  • Einstein A, Lush, III R, Rago R, Ko Y, Bubley G, Hener W, Beer T, Chatta G, Shepard R, Unger P, Merica E, Ette E, Harding M, Dalton W. A phase II study of the safety, pharmacokinetics and efficacy of Incel (biricodar, VX-710) in combination with mitoxantrone (M) and prednisone (P) in hormone refractory prostate cancer (HRPC). Clin Cancer Res. 1999;5:3836s-3836s. Pubmedid: noPMID.
  • Rimsza L, Campbell K, Dalton W, Salmon S, Wilcox G, Grogan T. The major vault protein (MVP), a new mulitdrug resistance associated protein, is frequently expressed in muliple myeloma. Leuk Lymphoma. 1999;34:315-324. Pubmedid: 10439368.
  • Coppola D, Schreiber R, Mora L, Dalton W, Karl R. Significance of FAS and RB protein expression during the progression of Barrett's metaplasia to adenocarcinoma. Ann Surg. 1999;6(3):298-304. Pubmedid: 10340890.
  • Sullivan D, Partyka J, Fields K, Goldstein S, Field T, Djulbegovic B, Perkins J, McIssac C, Lush, III R, Dalton W. A Phase I study of intensive-dose melphalan, topotecan and VP-16 phosphate (MTV) followed by autologous stem cell rescue in patients with multiple myeloma. Clin Cancer Res. 1999;5:3734s-3734s. Pubmedid: noPMID.
  • Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS, Jove R. Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10(1):105-115. Pubmedid: 10023775.
  • Dalton W. The tumor microenvironment as a determinant of drug response and resistance. Drug Resistance Updates. 1999;2:285-288. Pubmedid: 11504502.
  • Shtil A, Turner J, Durfee J, Dalton W, Yu H. Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: the role of cytotoxic T lymphocytes. Blood. 1999;93(6):1831-1837. Pubmedid: 10068654.
  • Niu G, Heller R, Catlett-Falcone R, Coppola D, Jaroszeski M, Dalton W, Jove R, Yu H. Gene therapy with dominant-negative stat3 suppresses growth of the murine melanoma beta16 tumor in vivo. Cancer Res. 1999;59(20):5059-5063. Pubmedid: 10537273.
  • Dalton W, Jove R. Drug resistance: approaches to circumvention. Semin Oncol. 1999;26(5):23-27. Pubmedid: 10528891.
  • Ross D, Yang W, Abruzzo L, Dalton W, Schneider E, Lage H, Dietel M, Greenberger L, Cole S, Doyle L. Atypical mulitdrug resistance: breast cancer resistance protein messenger RNA expression in mitozantrone-selected cell lines. J Natl Cancer Inst. 1999;91(5):429-433. Pubmedid: 10070941.
  • Catlett-Falcone R, Dalton W, Jove R. STAT proteins as novel targets for cancer therapy. Curr Opin Oncol. 1999;11(6):490-496. Pubmedid: 10550013.
  • Turner JG, Tan J, Crucian BE, Sullivan DM, Ballester OF, Dalton WS, Yang NS, Burkholder JK, Yu H. Broadened clinical utility of gene gun-mediated, granulocyte-macrophage colony-stimulating factor cDNA-based tumor cell vaccines as demonstrated with a mouse myeloma model. Hum Gene Ther. 1998 May;9(8):1121-1130. Pubmedid: 9625251.
  • Taylor C, Green S, Dalton W, Martino S, Rector D, Ingle J, Robert N, Budd T, Paradelo J, Natale R, Bearden J, Mailliard J, Osborne C. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol. 1998 Mar;16(3):994-999. Pubmedid: 9508182.
  • Miller T, Chase E, Dorr R, Dalton W, Lam K, Salmon S. A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease. Anticancer Drugs. 1998 Feb;9(2):135-140. Pubmedid: 9510499.
  • Kickhoefer V, Rajavel K, Scheffer G, Dalton W, Scheper R, Rome L. Vaults are up-regulated in multidrug-resistant cancer cell lines. J Biol Chem. 1998;273:8971-8974. Pubmedid: 9535882.
  • Izbicka E, Dalton W, Troyer D, Van Hoff D. Expression of two multidrug resistance genes in human prostatic carcinomas. J Natl Cancer Inst. 1998;90:166-167. Pubmedid: 9450583.
  • Lamy T, Liu J, Landowski T, Dalton W, Loughran, Jr. T. Dysregulation of Fas/Fas CD 95/CD95 ligand-apoptotic pathway in CD3+ large granular lymphocyte (LGL) leukemia. Blood. 1998;92:4771-4777. Pubmedid: 9845544.
  • Rosen S, Dalton W. Therapeutic modalities (Editorial). Curr Opin Oncol. 1998;10:523-524. Pubmedid: noPMID.
  • Watts GS, Pieper RO, Costello JF, Peng YM, Dalton WS, Futscher BW. Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol. 1997 Sep;17(9):5612-5619. Pubmedid: 9271436. Pmcid: PMC232409.
  • Wang H, Jiang Z, Wong YW, Dalton WS, Futscher BW, Chan VT. Decreased CP-1 (NF-Y) activity results in transcriptional down-regulation of topoisomerase IIalpha in a doxorubicin-resistant variant of human multiple myeloma RPMI 8226. Biochem Bioph Res Co. 1997 Aug;237(2):217-224. Pubmedid: 9268689.
  • Dalton WS. Detection of multidrug resistance gene expression in multiple myeloma. Leukemia. 1997 Jul;11(7):1166-1169. Pubmedid: 9205007.
  • Landowski T, Guzman M, Dalton W. Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood. 1997 Mar;89(6):1854-1861. Pubmedid: 9058704.
  • Taylor CW, Dalton WS, Mosley K, Dorr RT, Salmon SE. Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer. Breast Cancer Res Treat. 1997 Jan;42(1):7-14. Pubmedid: 9116320.
  • Dalton W. Detection of multidrug resistance gene expression in multiple myeloma. Leukemia. 1997;11:1166-1169. Pubmedid: 9298813.
  • Cellier M, Shustik C, Dalton W, Rich E, Hu J, Malo D, Schurr E, Gros P. Expression of the human NRAMP 1 gene in professional primary phagocytes: studies in blood cells and in HL-60 promyelocytic leukemia. J Leukoc Biol. 1997;61:96-105. Pubmedid: 9000542.
  • Chan H, Haddad G, Zheng L, Bradley G, Dalton W, Ling W. Sensitive immunoflorescence detection of the expression of P-glycoprotein in malignant cells. Cytometry. 1997;29:65-75. Pubmedid: 9298813.
  • Dalton W. Mechanisms of drug resistance in hematologic malignancies. Semin Hematol. 1997;34:3-8. Pubmedid: 9408955.
  • Landowski T, Qu N, Buyuksal I, Painter J, Dalton W. Mutations in the Fas antigen in patients with multiple myeloma. Blood. 1997;90(11):4266-4270. Pubmedid: 9373236.
  • Collins R, Shpilberg O, Drobyski W, Porter D, Giralt S, Champlin R, Goodman S, Wolff S, Hu W, Verfaille C, List A, Dalton W, Ognoskie N, Chetrit A, Antin J, Nemunatis J. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogenic bone marrow transplantation. J Clin Oncol. 1997;15:433-444. Pubmedid: 9053463.
  • Dalton W. Alternative (non-p-glycoprotein) mechanisms of drug resistance in non-hodgkin's lymphoma. Hematol Oncol Clin N Amer. 1997;11:975-986. Pubmedid: 9336726.
  • Abbaszadegan M, Cress A, Futscher B, Bellamy W, Dalton W. Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers. Cancer Res. 1996 Dec;56(23):5435-5442. Pubmedid: 8968098.
  • Futscher B, Foley N, Gleason-Guzman M, Meltzer P, Sullivan D, Dalton W. Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance. Int J Cancer. 1996 May;66(4):520-525. Pubmedid: 8635868.
  • Abbaszadegan M, Foley N, Gleason-Guzman M, Dalton W. Resistance to the chemosensitizer verapamil in a multi-drug-resistant (MDR) human multiple myeloma cell line. Int J Cancer. 1996 May;66(4):506-514. Pubmedid: 8635866.
  • List A, Spier C, Grogan T, Johnson C, Roe D, Greer J, Wolff S, Broxterman H, Scheffer G, Scheper R, Dalton W. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood. 1996 Mar;87(6):2464-2469. Pubmedid: 8630412.
  • Glasser L, Dalton WS, Fiederlein RL, Cook P, Powis G, Vogler WR. Response of human multiple myeloma-derived cell lines to alkyl-lysophospholipid. Exp Hematol. 1996 Feb;24(2):253-257. Pubmedid: 8641349.
  • Dalen JE, Dalton WS. Does lowering cholesterol cause cancer?. Jama. 1996 Jan;275(1):67-69. Pubmedid: 8531290.
  • Witherspoon SM, Emerson DL, Kerr BM, Dalton WS, Wissell PS. Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. Clin Cancer Res. 1996 Jan;2(1):7-12. Pubmedid: 9816083.
  • Beck W, Grogan T, Willman C, Cordon-Cardo C, Parham D, Kuttesch J, Andreef M, Bates S, Berard C, Boyett J, Brophy N, Broxterman H, Chan H, Dalton W, Dietel M, Fojo A, Gascoyne R, Head D, Houghton P, Srivastava D, Lehnert M, Leith C, Paietta E, Pavelic Z, Rimzsa L, Roninson I, Sikic B, Twentyman P, Warnke R, Weinstein R. Methods to detect P-glycoprotein-associated multidrug resistance: Consensus recommendations. Cancer Res. 1996;56(13):3010-3020. Pubmedid: 8674056.
  • Lehnert M, Degiuli R, Kunke K, Emerson S, Dalton W, Salmon S. Serum can inhibit reversal of mutlidrug resistance by chemosensitizers. Eur J Cancer. 1996;32A(5):862-867. Pubmedid: 9081367.
  • Anderson J, Heindl L, Bauman P, Ludi C, Dalton W. Cytokeratine expression results in a drug resistant phenotype to six different chemotherapeutic agents. Clin Cancer Res. 1996;2:97-105. Pubmedid: 9816096.
  • Salmon S, Dalton W. Relevance of multidrug resistance to rheumatoid arthritis: development of a new therapeutic hypothesis. J Rheum. 1996;23(44):97-101. Pubmedid: 8833064.
  • Zhao S, Consoli U, Arceci R, Pfeifer J, Dalton WS, Andreeff M. Semi-automated PCR method for quantitating MDR1 expression. Biotechniques. 1996;21(4):726-731. Pubmedid: 8891227.
  • Vogler WR, Berdel WE, Geller RB, Brochstein JA, Beveridge RA, Dalton WS, Miller KB, Lazarus HM. A phase II trial of autologous bone marrow transplantation (ABMT) in acute leukemia with edelfosine purged bone marrow. Adv Exp Med Biol. 1996;416:389-396. Pubmedid: 9131178.
  • Collins R, Shpilberg O, Drobyski W, Porter D, Giralt S, Champlin R, Goodman S, Wolff S, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin J, Nemunaitis J. Donor leukocyte infusions in 140 patients with relapsed malignancy after allgogenic bone marrow transplantation. J Clin Oncol. 1996;15(2):433-444.
  • Bellamy W, Odeleye A, Huizenga E, Dalton W. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts. Clin Cancer Res. 1995 Dec;1(12):1563-1570. Pubmedid: 9815957.
  • Klimecki W, Taylor C, Dalton W. Inhibition of cell-mediated cytolysis and P-glycoprotein function in natural killer cells by verapamil isomers and cyclosporine A analogs. J Clin Immunol. 1995 May;15(3):152-158. Pubmedid: 7559918.
  • Dalton WS, Crowley JJ, Salmon SS, Grogan TM, Laufman LR, Weiss GR, Bonnet JD. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer. 1995 Feb;75(3):815-820. Pubmedid: 7828131.
  • Guan X, Meltzer P, Dalton W, Trent J. Identification of cryptic sites of DNA sequence amplification in human breast cancer by chromosome microdissection. Nat Genet. 1995;8(2):155-161. Pubmedid: noPMID.
  • Neumunaitis J, Rosenfeld C, Ash R, Freedman M, Deeg J, Appelbaum F, Singer J, Flomenberg N, Dalton W, Elfenbein G, Rifkin R, Rubin A, Agosti J, Hayes F, Holcenberg J, Shadduck R. Phase III, double blind placebo controlled trial of rhGN-CSF following allogeneic bone marrow transplant. Bone Marrow Transplant. 1995;15:949-954. Pubmedid: 7581096.
  • Klimecki WT, Futscher BW, Dalton WS. Effects of ethanol and paraformaldehyde on RNA yield and quality. Biotechniques. 1994 Jun;16(6):1021-1023. Pubmedid: 7521184.
  • Bauman PA, Dalton WS, Anderson JM, Cress AE. Expression of cytokeratin confers multiple drug resistance. Proc Natl Acad Sci U S A. 1994 Jun;91(12):5311-5314. Pubmedid: 7515497. Pmcid: PMC43984.
  • Futscher BW, Abbaszadegan MR, Domann F, Dalton WS. Analysis of MRP mRNA in mitoxantrone-selected, multidrug-resistant human tumor cells. Biochem Pharmacol. 1994 Apr;47(9):1601-1606. Pubmedid: 8185674.
  • Haddad G, Thorner P, Bradley G, Dalton W, Ling V, Chan H. A sensitive multilayer immunoalkaline phosphatase method for detection of P-glycoprotein in leukemic and tumor cells in the bone marrow. Lab Invest. 1994;71(4):595-603.
  • Klimecki W, Futscher B, Dalton W. Effect of ethanol and paraformaldehyde on RNA yield and quality. Biotechniques. 1994;16:1021-1024.
  • Baumen P, Dalton W, Anderson J, Cress A. Expression of cytokeratin confers multiple drug resistance. Proc Natl Acad Sci U S A. 1994;91:5311-5314.
  • Klimecki W, Futscher B, Dalton W. Effects of cell-prevention with ethanol and paraformaldehyde on RNA yield and quality. Biotechniques. 1994;16:1021-1023.
  • Taetle R, Dos Santos B, Ohsugi Y, Koishihara Y, Yamada Y, Messner H, Dalton W. Effects of combined antigrowth factor receptor treatment on in vitro growth of multiple myeloma. J Natl Cancer Inst. 1994;86(6):450-455.
  • Dalton W. Is p-glycoprotein a potential target for reversing clinical drug resistance?. Curr Opin Oncol. 1994;6:595-600.
  • Klimecki W, Futscher B, Grogan T, Dalton W. P-gycoprotein expression and function in circulating blood cells from normal volunteers. Blood. 1994;83(9):2451-2458.
  • Futscher B, Abbaszadegan M, Domann F, Dalton W. Analysis of MRP mRNA in mitoxantrone-selected, multidrug-resistant human tumor cells. Biochem Pharmacol. 1994;49(9):1601-1606.
  • Chan H, Haddad G, Zheng L, Thorner P, Bradley G, Dalton W, Ling V. A sensitive multilayer immunofluorescent method for flow cytometric detection of P-glycoprotein in myeloma and tumor cells. Cytometry. 1994;71(4):595-603.
  • Abbaszadegan M, Futscher B, Klimecki W, Last A, Dalton W. Analysis of multidrug resistance-associated protein (MRP) mRNA in norman and malignant hematopoietic cells. Cancer Res. 1994;54:4676-4679.
  • Futscher BW, Blake LL, Gerlach JH, Grogan TM, Dalton WS. Quantitative polymerase chain reaction analysis of mdr1 mRNA in multiple myeloma cell lines and clinical specimens. Anal Biochem. 1993 Sep;213(2):414-421. Pubmedid: 8238918.
  • Bellamy WT, Odeleye A, Finley P, Huizenga B, Dalton WS, Weinstein RS, Hersh EM, Grogan TM. An in vivo model of human multidrug-resistant multiple myeloma in SCID mice. Am J Pathol. 1993 Mar;142(3):691-697. Pubmedid: 8456932. Pmcid: PMC1886807.
  • Grogan TM, Spier CM, Salmon SE, Matzner M, Rybski J, Weinstein RS, Scheper RJ, Dalton WS. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood. 1993 Jan;81(2):490-495. Pubmedid: 8093668.
  • Bellamy W, Odeleye A, Finley P, Huizenga E, Dalton W, Weinstein R, Hersh E, Grogan T. An in vivo model of human multidrug resitant multiple myeloma in SCID mice. Am J Pathol. 1993;142:691-697.
  • Trent J, Yang J, Emerson J, Dalton W, McGee D, Massey K, Thompson F, Villar H. Clonal chromosome abnormalities in human breast carcinoma II: 34 cases with metastic disease. Genes Chromosom Cancer. 1993;7:194-203.
  • Grogan T, Spier C, Salmon S, Matzner M, Rybski J, Weinstein R, Scheper R, Dalton W. P-glcoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood. 1993;81(2):490-495.
  • Schpeper R, Broxterman H, Scheffer G, Kaajik P, Dalton W, Heijninger T, Kalken C, Slovak M, Vries F, Valk P, Meijer C, Pinedo H. Overexpression of a Mr 110,000 vesicular protein in non-Ppglycoprotein-mediated multidrug resistance. Cancer Res. 1993;53:1475-1479.
  • List A, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W. PhaseI/II trial of Cyclosporine as a chemotherapy-resitance modifier in acute leukemia. J Clin Oncol. 1993;11(9):1652-1660.
  • Nemunaitis J, Rosenfeld C, Ash R, Flomenberg N, Friedman M, Deeg J, Appelbaum F, Singer J, Dalton W, Elfenbein G, Rifkin R, Rubin A, Agosti J, Hayes F, Shadduck R. Phase III double-blind trial of RHGM-CSF (sargramostin) following allogeneic bone marrow transplant (BMT). Blood. 1993;82:286a-286a.
  • Lehnert M, Emerson S, Dalton WS, de Giuli R, Salmon SE. In vitro evaluation of chemosensitizers for clinical reversal of P-glycoprotein-associated Taxol resistance. J Natl Cancer Inst Monogr. 1993;(15):63-67. Pubmedid: 7912531.
  • Thompson F, Emerson J, Dalton W, Yang J, McGee D, Villar H, Knox S, Massey K, Weinstein R, Bhattacharya A, Trent J. Clonal chromosome abnormalities in human breast carcinomas I: 28 cases with primary disease. Genes Chromosom Cancer. 1993;7:185-193.
  • Dalton W. Drug resistance modulation in the laboratory and the clinic. Semin Oncol. 1993;201(1):64-69.
  • Futscher BW, Campbell K, Dalton WS. Collateral sensitivity to nitrosoureas in multidrug-resistant cells selected with verapamil. Cancer Res. 1992 Sep;52(18):5013-5017. Pubmedid: 1387586.
  • Dalton WS, Salmon SE. Drug resistance in myeloma: mechanisms and approaches to circumvention. Hematol Oncol Clin North Am. 1992 Apr;6(2):383-393. Pubmedid: 1582980.
  • Bensinber W, Buckner C, Clift R, Petersen F, Bianco J, Singer J, Appelbaum F, Dalton W, Beatty P, Fefer A, Storb R, Thomas E, Hansen J. Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma. J Clin Oncol. 1992;10(9):1492-1497.
  • List A, Spier C, Dalton W. P-glcoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood. 1992;34:3-10.
  • Futscher B, Pieper R, Dalton W. Gene-specific DNA interstrand cros-links produced by nitrogen mustard in the human tumor cell line Colo320HSR. Cell Growth Differ. 1992;3(4):2117-223.
  • Futscher B, Campbell K, Dalton W. Collateral sensitivity to nitrosources in multi-drug resistant cells selected with verapamil. Cancer Res. 1992;52:5013-5017.
  • Futscher B, Pleper R, Dalton W, Erickson L. Gene-specific DNA interstrand cross-links produced by nitrogen mustard in the human tumor cell line Colo320HSR. Cell Growth Differ. 1992;3(4):217-223.
  • Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnert M, Roe DJ, Miller TP. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood. 1991 Jul;78(1):44-50. Pubmedid: 1676918.
  • Scheper RJ, Dalton WS, Grogan TM, Schlosser A, Bellamy WT, Taylor CW, Scuderi P, Spier C. Altered expression of P-glycoprotein and cellular adhesion molecules on human multi-drug-resistant tumor cells does not affect their susceptibility to NK- and LAK-mediated cytotoxicity. Int J Cancer. 1991 Jun;48(4):562-567. Pubmedid: 1710609.
  • Taylor CW, Dalton WS, Parrish PR, Gleason MC, Bellamy WT, Thompson FH, Roe DJ, Trent JM. Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. Brit J Cancer. 1991 Jun;63(6):923-929. Pubmedid: 1676902. Pmcid: PMC1972545.
  • Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM. Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res. 1991 Feb;51(3):995-1002. Pubmedid: 1988143.
  • Lehnert M, Dalton WS, Roe D, Emerson S, Salmon SE. Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. Blood. 1991 Jan;77(2):348-354. Pubmedid: 1670760.
  • Pennock GD, Dalton WS, Roeske WR, Appleton CP, Mosley K, Plezia P, Miller TP, Salmon SE. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst. 1991 Jan;83(2):105-110. Pubmedid: 1988684.
  • Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol. 1991 Jan;9(1):17-24. Pubmedid: 1670642.
  • Dalton WS, Grogan TM, Miller TP. The role of P-glycoprotein in drug-resistant hematologic malignancies. Cancer Treat Res. 1991;57:187-208. Pubmedid: 1686717.
  • Modiano MR, Dalton WS, Lippman SM, Joffe L, Booth AR, Meyskens FL. Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma. Invest New Drugs. 1990 Aug;8(3):317-319. Pubmedid: 2148744.
  • Modiano MR, Dalton WS, Lippman SM, Joffe L, Booth AR, Meyskens FL. Ocular toxic effects of fenretinide. J Natl Cancer Inst. 1990 Jun;82(12):1063. Pubmedid: 2140863.
  • Roberts RA, Cress AE, Dalton WS. Persistent intracellular binding of mitoxantrone in a human colon carcinoma cell line. Biochem Pharmacol. 1989 Dec;38(23):4283-4290. Pubmedid: 2597200.
  • Salmon SE, Soehnlen B, Dalton WS, Meltzer P, Scuderi P. Effects of tumor necrosis factor on sensitive and multidrug resistant human leukemia and myeloma cell lines. Blood. 1989 Oct;74(5):1723-1727. Pubmedid: 2790197.
  • Tong AW, Lee J, Wang RM, Dalton WS, Tsuruo T, Fay JW, Stone MJ. Elimination of chemoresistant multiple myeloma clonogenic colony-forming cells by combined treatment with a plasma cell-reactive monoclonal antibody and a P-glycoprotein-reactive monoclonal antibody. Cancer Res. 1989 Sep;49(17):4829-4834. Pubmedid: 2569359.
  • Harker WG, Slade DL, Dalton WS, Meltzer PS, Trent JM. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Cancer Res. 1989 Aug;49(16):4542-4549. Pubmedid: 2568172.
  • Salmon SE, Grogan TM, Miller T, Scheper R, Dalton WS. Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. J Natl Cancer Inst. 1989 May;81(9):696-701. Pubmedid: 2565403.
  • Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BG, Taylor CW, Miller TP, Salmon SE. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol. 1989 Apr;7(4):415-424. Pubmedid: 2564428.
  • Bellamy WT, Dalton WS, Meltzer P, Dorr RT. Role of glutathione and its associated enzymes in multidrug-resistant human myeloma cells. Biochem Pharmacol. 1989 Mar;38(5):787-793. Pubmedid: 2930579.
  • Dalton WS, Grogan TM, Rybski JA, Scheper RJ, Richter L, Kailey J, Broxterman HJ, Pinedo HM, Salmon SE. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood. 1989 Feb;73(3):747-752. Pubmedid: 2563664.
  • Peng YM, Dalton WS, Alberts DS, Xu MJ, Lim H, Meyskens FL. Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients. Int J Cancer. 1989 Jan;43(1):22-26. Pubmedid: 2521335.
  • Robert NJ, Dalton WS, Osborne CK, Abeloff M. Therapy in premenopausal women with advanced, oestrogen positive or/and progesterone positive breast cancer: surgical oophorectomy versus the LHRH analogue, Zoladex. Horm Res. 1989;32 Suppl 1:221-222. Pubmedid: 2533155.
  • Bellamy WT, Dorr RT, Dalton WS, Alberts DS. Direct relation of DNA lesions in multidrug-resistant human myeloma cells to intracellular doxorubicin concentration. Cancer Res. 1988 Nov;48(22):6360-6364. Pubmedid: 3180055.
  • Bellamy WT, Dalton WS, Kailey JM, Gleason MC, McCloskey TM, Dorr RT, Alberts DS. Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. Cancer Res. 1988 Nov;48(22):6365-6370. Pubmedid: 3180056.
  • Cress AE, Roberts RA, Bowden GT, Dalton WS. Modification of keratin by the chemotherapeutic drug mitoxantrone. Biochem Pharmacol. 1988 Aug;37(15):3043-3046. Pubmedid: 2456070.
  • Slovak ML, Hoeltge GA, Dalton WS, Trent JM. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Cancer Res. 1988 May;48(10):2793-2797. Pubmedid: 2896069.
  • Dalton WS, Cress AE, Alberts DS, Trent JM. Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. Cancer Res. 1988 Apr;48(7):1882-1888. Pubmedid: 2894893.
  • Durie BG, Dalton WS. Reversal of drug-resistance in multiple myeloma with verapamil. Brit J Haematol. 1988 Feb;68(2):203-206. Pubmedid: 3348977.
  • Dorr RT, Liddil JD, Trent JM, Dalton WS. Mitomycin C resistant L1210 leukemia cells: association with pleiotropic drug resistance. Biochem Pharmacol. 1987 Oct;36(19):3115-3120. Pubmedid: 3117061.
  • Dalton WS, Durie BG, Alberts DS, Gerlach JH, Cress AE. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res. 1986 Oct;46(10):5125-5130. Pubmedid: 2875788.
  • Garewal HS, Dalton WS. Metoclopramide in vincristine-induced ileus. Cancer Treat Rep. 1985 Nov;69(11):1309-1311. Pubmedid: 3867404.
  • Johnson JM, Lemberger L, Novotny M, Forney RB, Dalton WS, Maskarinec MP. Pharmacological activity of the basic fraction of marihuana whole smoke condensate alone and in combination with delta-9-tetrahydrocannabinol in mice. Toxicol Appl Pharm. 1984 Mar;72(3):440-448. Pubmedid: 6324414.
  • Dalton WS, Alberts DS. Mitoxantrone: a promising new chemotherapeutic agent. Ariz Med. 1984 Feb;41(2):96-98. Pubmedid: 6703919.
  • Salmon S, Grogan T, Miller T, Lehnert M, Dalton W. Clinical detectionof multidrug resistance an reversal with chemosensitizing agents. In: Drug resistance as a biochemical target in cancer chemotherapy. 13 ed. Academic Press; 1992;257-269.
  • Dalton W, Salmon S. Drug resistance in myeloma: mechanisms and approaches to circumvention. In: Barlogie B, ed. Hamatology/Oncology clinics of North America. Philadelphia, PA: WB Saunders Co; 1992;383-393.
  • Dalton W. Overcoming the multidrug-resistant phenotype. In: DeVita V, Hellman S, Rosenberg S, et al, eds. Cancer: principles and practice of oncology. 4th ed. Philadelphia, PA: J. B. Lippencott; 1993;2655-2666.
  • Fenstermacher DA, Wenham RM, Rollison DE, Dalton WS. Implementing personalized medicine in a cancer center. Cancer J. 17(6):528-536. Pubmedid: 22157297. Pmcid: PMC3240816.
  • Dorr R, Dalton W. Cancer chemotherapy in the elderly. In: Bressler R, Katz M, eds. Geriatric Pharmacology. New York, NY: McGraw Hill; 1993;535-583.
  • Hazlehurst L, Gros P, Dalton W. Chromosome mediated gene transfer of drug resistance to mitoxantrone. Anticancer Res. 18(2A):1005-1010. Pubmedid: 9615755.
  • Dalton WS, Martz R, Rodda BE, Lemberger L, Forney RB. Influence of cannabidiol on secobarbital effects and plasma kinetics. Clin Pharmacol Ther. 1976 Dec;20(6):695-700. Pubmedid: 791563.
  • Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB. Effects of marihuana combined with secobarbital. Clin Pharmacol Ther. 1975 Sep;18(3):298-304. Pubmedid: 1100299.
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions